Available Technological Offer
Natural nutraceutical to promote the prevention of the cancer stem cells (CSCs) phenotype acquisition at the origin of tumor regrowth, metastasis and relapse.
A new immunotherapy strategy based on the administration of a monoclonal antibody specific for pre-TCR has been developed and validated in a preclinical human T-ALL xenotransplantation model in mice.
Novel Hydrogel with optimized mechanical and structural properties to resemble artificial lymph nodes and improve primary human CAR-T cell manufacture.
Design of a novel proteolytic set of chimeras (26STACs) directed at the degradation of the ceramide transfer protein CERT-1 by the proteasome, in an E3-independent manner, for its use in the treatment of breast cancer.
Effective triple-negative breast cancer treatment based on the modulation of the phenotype of CD206+ tumor associated macrophages by means of a novel peptide-drug-conjugate (PDC) which is able to slow tumor progression and supress lung metastasis.
New tiourea- and urea-based glycolipids with immunomodulatory activity. The compounds are Mincle agonist and have shown in vitro and in vivo immunostimulant activity. They can be used as vacine adjuvants, in the modulation of the immune response and in the treatment of infectious disease or cancer.
Low-cost method with high effectiveness for the diagnosis and prognosis of thyroid cancers that are difficult to resolve during preoperative evaluation. It provides a malignancy score measuring the methylation level of various CpG sites determined by a machine learning classification system.
New carbon nanocapsules filled with enriched lithium compounds that can be applied in NCT for cancer treatment
System based on an algorithm that allows for highly accurate diagnosis of breast cancer through the analysis of stochastic intracellular fluctuations of tumor cells, using images obtained through digital microscopy.